mcrae12 copy & paste, page-7

thanks for the reply macrae.i thought those questions would be a bit hard to answer..its no personal attack but if you feel so strongly against prr i just would like to find out why considering them posts of yours about eugene kopp being a director and ian frazer being of no use to prr when he was when you were a holder..some good debate is healthy for us holders to find out more but only if there is truth behind them..if you dont want to though its your right to not answer..thanks anyway and aprreciate you effort in answering my questions..one last one though if you could.

with your bioshares spec but class c statement..i cant seem to find that as in the last bioshares write up they have a wait as they say wait till ind status os given.and all past bioshares issues that i can find say spec buy class A.im sure prr have more than 1 product as you know with crypto being 1 that is being dicussed with a major pharma for jv...here it is..


Summary
Prima Biomed looks to have found, after several tumultuous years,
a stronger footing and a clearer focus, with the commercialisation
of CVac its principle goal. The company also holds three other
assets which it aims to divest. The CVac product warrants continued
clinical investigation and the current treatment regimes for
ovarian cancer are unsatisfactory.
Prima Biomed is a stock to watch. However, we recommend that
investors wait until the FDA 'approves' the company's IND application
and full clinical trial protocol details are made available by
the company. When that event occurs, a more timely and detailed
assessment of the clinical and funding risks in front of the company
can be made.
Bioshares recommendation: Wait